Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 2/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324815 | 0.84 | SGK1 (0.31) | SGK1 | |
| SCHEMBL8212888 | 0.76 | ADORA2A (0.34) | MAP2K4GRM4 | |
| SCHEMBL10220228 | 0.75 | KDR (0.37) | MAP2K4GRM4 | |
| SCHEMBL14738326 | 0.72 | MAP2K4 (0.33) | MAP2K4GRM4 | |
| SCHEMBL2955386 | 0.72 | MAP2K4 (0.37) | MAP2K4GRM4 | |
| SCHEMBL16680979 | 0.72 | MAP4K4 (0.44) | SGK1 | |
| SCHEMBL1163212 | 0.71 | CHEK1 (0.31) | MAP2K4GRM4 | |
| SCHEMBL10219959 | 0.71 | MAP2K4 (0.51) | MAP2K4 | |
| SCHEMBL17515576 | 0.70 | TRPA1 (0.36) | MAP2K4 | |
| SCHEMBL26014241 | 0.70 | GRM4 (0.41) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | SGK1 3814/4885MAP2K4 3889/4885GRM4 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.